A first-in-patient 18-week study of galvokimig, a multispecific antibody-based therapeutic targeting interleukin (IL)-13, IL-17A, and IL-17F in participants with moderate-to-severe atopic dermatitis (AD)

Authors
Category Primary study
JournalJournal of investigative dermatology
Year 2025
This article has no abstract
Epistemonikos ID: 20aea834e8d4762893df566e246db4c9679e5a97
First added on: Feb 28, 2026